Zoetis’ (ZTS) “Hold” Rating Reaffirmed at Argus

Zoetis (NYSE:ZTS)‘s stock had its “hold” rating restated by investment analysts at Argus in a note issued to investors on Wednesday,Benzinga reports.

A number of other research analysts also recently issued reports on the company. UBS Group cut their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Morgan Stanley reiterated an “overweight” rating and set a $115.00 price objective on shares of Zoetis in a research note on Friday, May 15th. Citigroup cut their price objective on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Finally, Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Six research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $133.92.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $80.36 on Wednesday. Zoetis has a fifty-two week low of $72.38 and a fifty-two week high of $172.23. The business has a 50-day simple moving average of $106.72 and a two-hundred day simple moving average of $117.88. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The firm has a market cap of $33.69 billion, a price-to-earnings ratio of 13.33, a price-to-earnings-growth ratio of 1.33 and a beta of 0.87.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the previous year, the company earned $1.48 EPS. Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, analysts expect that Zoetis will post 6.88 earnings per share for the current year.

Insider Activity at Zoetis

In related news, Director Michael B. Mccallister purchased 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have purchased 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Institutional Trading of Zoetis

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Glenmede Trust Co. NA increased its stake in Zoetis by 36.5% in the first quarter. Glenmede Trust Co. NA now owns 231,874 shares of the company’s stock worth $27,410,000 after purchasing an additional 62,034 shares during the period. Axiom Investment Management LLC purchased a new stake in Zoetis in the first quarter worth $99,000. Summitry LLC purchased a new stake in Zoetis in the first quarter worth $21,255,000. Segall Bryant & Hamill LLC bought a new position in shares of Zoetis during the 1st quarter worth $10,036,000. Finally, Wellington Grp LLC grew its position in shares of Zoetis by 6,675.0% during the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after buying an additional 267 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.